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Biostatistics, College of Public Health, University of Kentucky, Lexington, KY, United States, 3 College of Medicine, University 
of Kentucky, Lexington, KY, United States, 4 Children’s Hospital of Michigan, Detroit, MI, United States, 5 Department of 
Pediatrics, New Jersey Medical School, Newark, NJ, United States, 6 Department of Biomedical Engineering, College of 
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introduction: Intermittent hypoxemia (IH) is defined as episodic drops in oxygen satura-
tion (SpO2). Preterm infants are at increased risk for IH due to their immature respiratory 
control/apnea of prematurity. The clinical relevance of IH is a relatively new observation 
with rising evidence linking IH to neonatal morbidities and long-term impairment. Hence, 
assessing factors that influence IH in preterm infants is imperative. Given the epidemic of 
opioid misuse in the USA, there is an urgent need to understand the impact of prenatal 
opioid exposure on neonatal outcomes. Hence, we wanted to assess the relationship 
between isolated prenatal opioid exposure and IH in preterm infants.
Methods: In order to accurately calculate IH, SpO2 data were prospectively collected 
using high-resolution pulse oximeters during the first 8 weeks of life in preterm infants 
less than 30 weeks gestational age. Data related to prenatal opioid misuse were retro-
spectively collected from medical charts. Infants with tobacco or poly-drug exposure 
were excluded. The primary outcome measure is percent time spent with SpO2 below 
80% (%time-SpO2 < 80). The secondary outcome measure is the number of severe IH 
events/week with SpO2 less than 80% (IH-SpO2 < 80).
results: A total of 82 infants with isolated opioid exposure (n =  14) or who were 
unexposed (n =  68) were included. There were no significant differences in baseline 
characteristics between opioid exposed and unexposed groups. There was a statisti-
cally significant increase of 0.23 (95% CI: 0.03, 0.43, p = 0.03) in mean of the square 
root of %time-SpO2 < 80. The number of IH-SpO2 < 80 events was higher in the opioid 
exposed group (mean difference = 2.95, 95% CI: −0.35, 6.25, p-value = 0.08), although 
statistical significance was not quite attained.
conclusion: This study shows that preterm infants prenatally exposed to opioids have 
increased IH measures compared to unexposed infants. Interestingly, the increased IH in 
the opioid exposed group persists beyond the immediate postnatal period.
Keywords: prenatal, opioid exposure, opiates, intermittent hypoxemia, apnea, preterm infants
Abbreviations: GA, gestational age; IH, intermittent hypoxemia; NICU, neonatal intensive care unit; SIDS, sudden infant death 
syndrome; SpO2, oxygen saturation; THC, tetrahydrocannabinol.
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inTrODUcTiOn
Intermittent hypoxemia (IH) is defined as brief, episodic drops in 
oxygen saturation (SpO2) (1, 2). Preterm infants are at increased 
risk for IH due to their respiratory control instability/apnea of 
prematurity superimposed on immature lung structure/func-
tion. IH in preterm infants can persist beyond discharge from 
the neonatal intensive care unit (NICU) (3). Brief episodes of 
oxygen desaturations may seem clinically insignificant, but 
these IH episodes, occurring up to hundreds of times per day, 
have a cumulative effect on neonatal morbidity and mortality. 
There is ample evidence showing a significant effect of IH on 
neurocognitive handicap, decreased neuronal integrity, increased 
inflammation and oxidative stress, and impaired growth (4, 5). 
Furthermore, IH has been linked to severe retinopathy of pre-
maturity and long-term neurodevelopmental impairment such 
as worse language and motor outcomes (2, 6–9). The clinical 
relevance of IH is a relatively new observation with the advent of 
high-resolution pulse oximeters and assessing factors that influ-
ence IH is imperative.
There is a rise in substance misuse in the USA reaching a 
nationwide epidemic (10–15). There is an urgent need to 
understand the impact of prenatal opioid exposure on neonatal 
outcomes (5). Opioid exposure is associated with long-term neu-
robehavioral and developmental impairment in infants (16–23). 
Opioids are known to suppress breathing and respiratory effort 
especially in neonates (24). Since most mothers who misuse 
opioids have also been found to smoke and use poly-drugs 
that affect breathing pattern, it has been challenging to assess 
the isolated effect of prenatal opioid exposure on respiratory 
outcomes. Prenatal tobacco exposure alters respiratory control 
and worsens lung function (25–29). Prenatal exposure to other 
illicit drugs such as cocaine perturbs maturation of respiratory 
control, resulting in disruption of postnatal respiration (30). 
Only few studies were able to assess the effect of isolated opioid 
exposure on neonatal respiratory outcomes. However, these 
studies included mostly later preterm and term infants or were 
limited to short monitoring times and small sample sizes (31, 
32). In this study, we utilize continuous high-resolution pulse 
oximeters to assess the relationship between isolated prenatal 
opioid exposure and IH in preterm infants during the first 
2 months of life.
MaTerials anD MeThODs
study Design and Data collection
Oxygen saturation data were prospectively collected from 130 
preterm infants less than 30 weeks gestational age (GA) admitted 
to our level 4 NICU between November 2014 and April 2017. 
We used high-resolution pulse oximeters (Radical 7: Masimo, 
Irvine, CA, USA) set at 2 s averaging time and 1 Hz sampling rate 
to continuously monitor patients during the first 8 weeks of life. 
In order to differentiate intermittent from sustained hypoxemia, 
we included events between 4 and 180 s (1). The exact threshold 
below which IH is clinically significant is controversial. A drop in 
SpO2 to less than 80% is widely considered to be clinically relevant 
(1, 2, 6). Therefore, the primary outcome measure was defined 
as percent time spent with SpO2 below 80% (%time-SpO2 < 80). 
The secondary outcome measure was defined as the number of 
severe IH events with SpO2 less than 80% (IH-SpO2 < 80). Other 
outcome measures such as length of stay and neonatal morbidi-
ties were collected.
Pulse oximeters were equipped with serial data recorders 
(Acumen Instruments Corp.) for continuous data collection. 
Novel programs were utilized to filter and analyze data (Matlab, 
Natick, MA, USA) (1, 33). Data with artifacts were excluded. 
Only SpO2 data with good signal were included in the analyses. 
Preterm infants less than 30  weeks GA were included. Infants 
with major congenital malformations were excluded.
Data related to substance misuse and tobacco use were ret-
rospectively collected from medical charts. If a mother chroni-
cally used prenatal opioids and/or the maternal/neonatal drug 
screens were positive for opioids, then the infant was considered 
for screening. Infants were then excluded from the study if the 
mother used tobacco, alcohol, or other drugs (such as cannabis); 
i.e., in order to assess for isolated opioid exposure, patients with 
any other exposure were excluded. Infants in our cohort who were 
not exposed to opioids, tobacco, or other drugs served as controls. 
Neonatal meconium or urine drug screens are performed in the 
immediate newborn period. Positive drug screens due to opioids 
and other medications used for pain or sedation during delivery 
were excluded, as they do not represent prenatal misuse. Tobacco 
and alcohol use were collected from mothers’ medical records, as 
the toxicology screens at our hospital do not test for alcohol or 
tobacco exposure. The study was approved by the University of 
Kentucky Institutional Review Board, and informed consent was 
obtained prior to SpO2 data acquisition.
statistical analysis
Descriptive statistics for continuous variables are presented as 
either the mean with SD or median with interquartile range, and 
frequencies and percentages are given for categorical variables. 
Two-sample t-tests and Wilcoxon two-sample tests were used 
to compare opioid exposure to non-exposure with respect to 
continuous variables, and chi-square or Fisher’s exact tests were 
used for categorical variables. To compare opioid exposure to 
non-exposure with respect to IH measures over time, we utilized 
multivariate Gaussian linear modeling in order to account for 
repeated measurements from subjects, and to adjust for the 
potential confounders of GA, birth weight, APGAR score at 
5 min of life, gender, and the use of prenatal steroids. In order to 
meet statistical assumptions in these models, the square root of 
the IH measures was taken. Furthermore, weekly observations 
were weighted by the percentage of time IH was tracked during 
the given week. Analyses were conducted in SAS version 9.4 (SAS 
Institute, Cary, NC, USA), and all tests were two-sided with a 5% 
significance level.
resUlTs
Of the 127 infants in our database with complete data sets, 19.7, 
29.1, and 4.7% were prenatally exposed to opioids, tobacco, and 
cannabis, respectively. None were exposed to alcohol, cocaine, 
and other illicit drugs. Opioid exposed infants were positive for 
TaBle 2 | Neonatal morbidities and outcomes.
Opioid 
exposed
Unexposed p-Value
N = 14 N = 68
Received surfactant 14 (100%) 62 (91%) 0.58
Respiratory distress syndrome 14 (100%) 67 (99%) 1
Oxygen at 28 days of life 10 (71%) 39 (57%) 1
Oxygen at 36 weeks corrected age 7 (50%) 19 (28%) 0.26
Oxygen at discharge 9 (64%) 30 (44%) 0.18
Severe bronchopulmonary dysplasia 9 (64%) 27 (46%) 0.21
Postnatal steroids use for lung disease 6 (43%) 19 (29%) 0.35
Pneumothorax 1 (7%) 2 (3%) 0.43
Patent ductus arteriosus 8 (57%) 24 (35%) 0.13
Necrotizing enterocolitis 0 (0%) 2 (3%) 1
Late onset sepsis 3 (21%) 9 (13%) 0.43
Mortality 0 (0%) 9 (13%) 0.35
Length of stay (days) 85 (59, 101) 68 (56, 91) 0.32
Frequency (%), median (interquartile range).
TaBle 1 | Baseline characteristics.
Opioid exposed Unexposed p-Value
N = 14 N = 68
Gestational age (weeks) 27.0 ± 2.1 27.0 ± 1.6 0.97
Birth weight (g) 948 ± 263 928 ± 247 0.79
Male 6 (43%) 23 (34%) 0.54
Apgar 5 min 7 (6, 7.5) 6 (5, 7) 0.21
Prenatal steroids 12 (86%) 61 (91%) 0.62
Mean ± SD, median (interquartile range).
FigUre 1 | Flow diagram for patient eligibility.
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buprenorphine metabolites (64%), oxycodone (16%), and other 
opioids such as heroin and fentanyl (20%). A total of 82 infants 
qualified for analysis as they were either unexposed to any illicit 
drug/tobacco (n =  68) or exposed to opioids only (n =  14). 
Figure  1 presents the flow diagram for patient eligibility and 
exclusion.
There were no significant differences in baseline characteristics 
as presented in Table 1. The mean GA was 27 weeks in both groups. 
There were no significant differences in birth weight, gender, and 
Apgar scores at 5 min of life. The vast majority of infants received 
prenatal steroids with no difference between groups. There were 
no significant differences in respiratory outcomes and neonatal 
morbidities between groups as presented in Table 2. Our cohort 
included preterm infants less than 30 weeks GA. Essentially all 
infants had respiratory distress syndrome and received surfactant. 
Severe bronchopulmonary dysplasia, postnatal steroids use for 
lung disease, and oxygen need at 28 days, 36 weeks postmenstrual 
age, and at discharge did not differ between opioid exposed and 
unexposed groups (all p = NS). Other neonatal morbidities such 
as patent ductus arteriosus, late onset sepsis, and necrotizing 
enterocolitis did not differ between groups (all p = NS). None 
of the exposed infants died versus nine deaths in the unexposed 
group (p = 0.35). The median length of stay was 17 days longer 
in the opioid group (85  days) compared to unexposed group 
(68  days); however, the results were not statistically significant 
(p = 0.32).
There was a statistically significant increase in our primary 
outcome measure, %time-SpO2 < 80, as represented in Figure 2. 
The estimated difference in the means of the square root of 
%time-SpO2 < 80 was 0.23 (95% CI: 0.03, 0.43, p = 0.03). The 
mean number of IH events was estimated to be 2.95 (95% CI: 
−0.35, 6.25, p-value = 0.08) higher in the opioid exposed group, 
as represented in Figure 3; however, this did not reach statistical 
significance. Note that these results represent the square root of 
means in order to meet statistical assumptions in these models; 
estimated medians for IH measures are calculated using our 
model results and are presented in Figures  2B and 3B. Given 
increased death in the unexposed group, we then analyzed data 
excluding deaths, and results were similar. Specifically, there 
was a statistically significant increase in our primary outcome 
measure (%time-SpO2 < 80) in the opioid exposed compared to 
the unexposed group, with an estimated mean difference (square 
root) of 0.24 (95% CI: 0.05, 0.44, p-value = 0.02). Furthermore, 
the mean number of IH events was estimated to be 2.98 (95% CI: 
−0.20, 6.16, p-value = 0.07) higher in the opioid exposed group, 
not quite reaching statistical significance.
DiscUssiOn
These results suggest that prenatal opioid exposure is associated 
with increased IH measures compared to unexposed preterm 
infants. This study has two main findings. First, interestingly, 
the increased IH measures in opioid exposed infants persisted 
beyond the early postnatal period. Preterm infants were continu-
ously monitored with high-resolution pulse oximeters during the 
first 2 months of life. Second, we had the unique opportunity to 
assess the relationship between isolated opioid exposure and 
respiratory instability in preterm infants. It was challenging in the 
past to assess the relationship between isolated prenatal opioid 
FigUre 3 | (a) Preterm infants exposed to prenatal opioids did not have a significant increase in number of intermittent hypoxemia (IH) events per week (IH-
SpO2 < 80) compared to unexposed infants (p = 0.08). The model adjusted for gestational age, birth weight, gender, prenatal steroids, and Apgar scores at 5 min of 
life. (B) This figure demonstrates the estimated average IH-SpO2 < 80 medians of opioid exposed versus unexposed preterm infants calculated using the adjusted 
model results. Sqrt, square root.
FigUre 2 | (a) Preterm infants exposed to prenatal opioids had increased time spent with oxygen saturation less than 80% (%time-SpO2 < 80) compared to 
unexposed infants (p = 0.03). The model adjusted for gestational age, birth weight, gender, prenatal steroids, and Apgar scores at 5 min of life. (B) This figure 
demonstrates the estimated average %time-SpO2 < 80 medians in both groups calculated using the adjusted model results. Sqrt, square root.
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exposure and respiratory outcomes/IH, as the majority of women 
who use opioids also smoke or misuse poly-drugs. Given our 
cohort demographics, we had the ability to report this association 
in infants exposed to opioids only.
Another interesting secondary finding in our study is the 
steady increase in IH in the first month of life before plateauing 
and then decreasing. This natural progression of IH has been 
described before from another cohort of preterm infants less than 
28 weeks GA (1, 2). Our study replicates this finding from a new 
cohort of preterm infants less than 30 weeks GA. The rise in IH 
may be related to peripheral chemoreceptor dysregulation and 
development of lung disease (34).
Patients in our opioid exposed and unexposed groups did not 
significantly vary in terms of baseline characteristics (such as age, 
weight, gender) and neonatal morbidities (such as lung disease, 
patent ductus arteriosus, late onset sepsis, and necrotizing 
enterocolitis). In addition, we adjusted in the model for factors 
that may influence oxygenation in preterm infants such as GA 
and prenatal steroids. The finding of nine deaths in the unexposed 
group compared to no deaths in the opioid exposed group may 
be due to chance. Secondary analyses excluding deaths showed 
similar results with increased IH in the opioid exposed group. A 
significant secondary finding in this study is the high prevalence 
of tobacco and drug exposure in our cohort of preterm infants. 
The frequency of opioid exposure in our preterm population is 
higher than previously reported, thus creating urgency toward 
addressing this significant problem in this vulnerable patient 
population (10, 12–15).
There are multiple proposed mechanisms by which prenatal 
opioid exposure may affect breathing patterns and subsequent 
persistent IH in preterm infants. Prenatal opioid exposure alters 
the response to carbon dioxide and depresses central respiratory 
control centers (31, 35–38); a main driver for respiratory output. 
Olsen and Lees demonstrated a blunted response to carbon 
5Abu Jawdeh et al. Prenatal Opioid Exposure and IH
Frontiers in Pediatrics | www.frontiersin.org December 2017 | Volume 5 | Article 253
dioxide in methadone exposed infants compared to controls 
(31). Ali et  al. compared the response to hypercarbia among 
three groups of term patients who were exposed to tobacco/
substance misuse, tobacco alone, and unexposed controls. The 
authors showed a lower increase in central respiratory drive in 
response to hypercarbia in infants exposed to substance misuse 
as compared to tobacco alone and unexposed controls (35). 
Another mechanism that explains our results may be related to 
in utero hypoxia related to opioids. Prenatal opioids, especially 
street heroin, cause chronic intrauterine hypoxia leading to 
brainstem gliosis, resulting in injury to the central respiratory 
network. This may lead to respiratory instability and subse-
quent IH (36). Finally, data from animal models showed that 
exposure to opioid agonists caused downregulation of placental 
neurotransmitter receptors (39). Abnormalities or depletion 
of receptor sites, especially if the same process occurs in the 
fetal brain, could impair the function of the normal neonatal 
respiratory control network leading to frequent or prolonged 
apnea and subsequent IH.
Many studies have assessed the impact of prenatal opioid 
exposure on sudden infant death syndrome (SIDS) in infants with 
controversial results. This study does not address SIDS; rather, it 
focuses on IH, the end result of apnea of prematurity. However, 
the mechanism by which prenatal opioid exposure is associated 
with increased SIDS and IH may be similar. Although our study 
period focused on the inpatient setting, it is plausible that opioid 
exposed infants continue to have increased cardiorespiratory 
events/IH after discharge. Interestingly, compared to unexposed 
infants, opioid exposed infants had a trend toward longer length 
of stay (68 versus 85 days, p = NS), which may be related, in part, 
to persistent cardiorespiratory events.
A major limitation of this study is that data related to exposure 
were retrospectively collected. Another limitation is a lack of 
reporting daily caffeine use and daily respiratory support settings. 
At our center, virtually all infants with GA less than 30 weeks are 
started on caffeine therapy. Furthermore, our study focused on IH 
events and lacked reporting of apnea and bradycardia events. Lack 
of addressing heart rate is a limitation since bradycardia events 
may be associated with poor long-term outcomes (6). Another 
limitation is the small sample size; however, our sample size of 
isolated opioid exposure is relatively large compared to existing 
literature. This is a single center study; hence, our results may not 
be generalizable. Finally, we did not compare the long-term neu-
rodevelopmental outcomes for exposed versus unexposed infants.
cOnclUsiOn
There is rising evidence linking IH to neonatal morbidities and 
impairment. However, the exact threshold (frequency, duration, 
severity) by which IH leads to injury in preterm infants needs 
further investigation; i.e., any increase in IH may be associated 
with impairment in preterm infants. Furthermore, there is a need 
to understand factors, such as prenatal opioid exposure, that may 
influence IH and subsequently increase neonatal morbidities. 
In this study, we show an association between prenatal opioid 
exposure and increased IH measures in preterm infants. Studies 
to address the relationship between opioid exposures, IH, and 
long-term neurodevelopmental outcomes are imperative. Given 
the rising epidemic of opioid misuse in the USA, understanding 
the relationship between opioid exposure, IH and long-term 
impairment is imperative. A larger prospective study aimed at 
understanding these relationships may have a direct impact on 
short- and long-term management of preterm infants.
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